Jacobson Pharma (2633) Releases Interim Results for Six Months Ended September 2025

Bulletin Express

Nov 18, 2025

Jacobson Pharma Corporation Limited (Stock Code: 2633) announced its interim results for the six months ended 30 September 2025. Revenue was approximately HK$766.6 million, a 5.4% decrease compared to HK$810.0 million in the corresponding period of 2024. Profit from operations reached about HK$183.4 million, down 6.3% from HK$195.8 million last year.

Notably, profit attributable to equity shareholders rose by around 1.2% to HK$142.0 million, compared to HK$140.3 million a year ago. Management attributed the softened revenue to an early end to the flu season but noted that strong demand for chronic disease medications supported overall performance.

The board declared an interim dividend of HK4.25 cents per Share, representing a 21.4% increase from HK3.50 cents in 2024. Ongoing enhancements in manufacturing capacity, research and development advancements, and strategic partnerships are expected to further support the company’s competitiveness in the healthcare sector in Hong Kong and selected Asian markets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127622744"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127622744\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127622744?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 18:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127622744","market":"hk","top_or_hot":-1,"title":"Jacobson Pharma (2633) Releases Interim Results for Six Months Ended September 2025","media":"Bulletin Express","content":"<p>Jacobson Pharma Corporation Limited (Stock Code: 2633) announced its interim results for the six months ended 30 September 2025. Revenue was approximately HK$766.6 million, a 5.4% decrease compared to HK$810.0 million in the corresponding period of 2024. Profit from operations reached about HK$183.4 million, down 6.3% from HK$195.8 million last year.</p>\n<p>Notably, profit attributable to equity shareholders rose by around 1.2% to HK$142.0 million, compared to HK$140.3 million a year ago. Management attributed the softened revenue to an early end to the flu season but noted that strong demand for chronic disease medications supported overall performance.</p>\n<p>The board declared an interim dividend of HK4.25 cents per Share, representing a 21.4% increase from HK3.50 cents in 2024. Ongoing enhancements in manufacturing capacity, research and development advancements, and strategic partnerships are expected to further support the company’s competitiveness in the healthcare sector in Hong Kong and selected Asian markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jacobson Pharma (2633) Releases Interim Results for Six Months Ended September 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJacobson Pharma (2633) Releases Interim Results for Six Months Ended September 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-18 18:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jacobson Pharma Corporation Limited (Stock Code: 2633) announced its interim results for the six months ended 30 September 2025. Revenue was approximately HK$766.6 million, a 5.4% decrease compared to HK$810.0 million in the corresponding period of 2024. Profit from operations reached about HK$183.4 million, down 6.3% from HK$195.8 million last year.</p>\n<p>Notably, profit attributable to equity shareholders rose by around 1.2% to HK$142.0 million, compared to HK$140.3 million a year ago. Management attributed the softened revenue to an early end to the flu season but noted that strong demand for chronic disease medications supported overall performance.</p>\n<p>The board declared an interim dividend of HK4.25 cents per Share, representing a 21.4% increase from HK3.50 cents in 2024. Ongoing enhancements in manufacturing capacity, research and development advancements, and strategic partnerships are expected to further support the company’s competitiveness in the healthcare sector in Hong Kong and selected Asian markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02633","symbol_name":"雅各臣科研制药","start_time":0,"source_url":"","article_id":"1127622744","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127622744","pubTimestamp":1763461359,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Jacobson Pharma Corporation Limited (Stock Code: 2633) announced its interim results for the six months ended 30 September 2025. Revenue was approximately HK$766.6 million, a 5.4% decrease compared...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02633":"雅各臣科研制药"},"translate_title":"雅各臣药业(2633)发布截至2025年9月止六个月中期业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02633":1},"content_text":"Jacobson Pharma Corporation Limited (Stock Code: 2633) announced its interim results for the six months ended 30 September 2025. Revenue was approximately HK$766.6 million, a 5.4% decrease compared to HK$810.0 million in the corresponding period of 2024. Profit from operations reached about HK$183.4 million, down 6.3% from HK$195.8 million last year.\nNotably, profit attributable to equity shareholders rose by around 1.2% to HK$142.0 million, compared to HK$140.3 million a year ago. Management attributed the softened revenue to an early end to the flu season but noted that strong demand for chronic disease medications supported overall performance.\nThe board declared an interim dividend of HK4.25 cents per Share, representing a 21.4% increase from HK3.50 cents in 2024. Ongoing enhancements in manufacturing capacity, research and development advancements, and strategic partnerships are expected to further support the company’s competitiveness in the healthcare sector in Hong Kong and selected Asian markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}